| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184781 | Gynecologic Oncology | 2011 | 5 Pages |
ObjectivesThe aim of this study was to determine the maximum tolerated dose and dose-limiting toxicity (DLT) of whole abdomen radiation as a chemosensitizer of weekly docetaxel for women with recurrent epithelial ovarian fallopian tube, or peritoneal cancers.Patients and methodsWomen were enrolled on one of three dose levels of docetaxel (20, 25, or 30Â mg/m2) administered weekly with concurrent low-dose whole abdominal radiation given as 60Â cGy bid 2Â days weekly for a total of 6Â weeks.ResultsThirteen women were enrolled and received 70 weekly treatments of docetaxel in combination with radiation therapy. At the first dose level, docetaxel 25Â mg/m2, grade 3 fatigue and thrombocytopenia were observed. At the next dose level, docetaxel 30Â mg/m2, grade 3 febrile neutropenia, grade 4 thrombocytopenia with epistaxis, and grade 3 diarrhea were observed. Given these dose-limiting toxicities, a lower dose of docetaxel 20Â mg/m2 was administered and found to be tolerable. No objective responses were observed among the 10 patients with measurable disease; however, the median progression-free survival (PFS) in all patients was 3.3Â months, and 3 of the patients with measurable disease were free of tumor progression after 6Â months (30%; 90% confidence interval 8.7-61%).ConclusionsTwice weekly low-dose whole abdomen radiation during weekly docetaxel 20Â mg/m2 was well-tolerated. Given the PFS demonstrated in these women with resistant ovarian cancer, further study of whole abdominal radiation and concurrent chemotherapy may be warranted.
Research HighlightsâºRadiotherapy is a chemosensitizer to docetaxel in the treatment of ovarian cancer. âºChemoradiation resulted in stable disease in women with recurrent ovarian cancer. âºRadiotherapy with docetaxel is tolerable in women with recurrent ovarian cancer.
